Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human HER2-targeted CAR-M cells
- Development stage
- Unknown
- Lead developer
- Hangzhou First People's Hospital
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intraperitoneal
01
Overview
**Human HER2-targeted CAR-M cells** are an autologous cell therapy being developed by **First People's Hospital of Hangzhou** for **HER2-positive advanced gastric cancer with peritoneal metastases**. The product consists of patient-derived macrophages genetically engineered using an **adenoviral vector** to express a **chimeric antigen receptor** containing an anti-HER2 single-chain antibody domain, enabling recognition of **human epidermal growth factor receptor 2** on tumor cells. In the reported exploratory clinical-trial setting, the cells are administered **intraperitoneally** with the intent to produce anti-tumor immune activity against HER2-expressing gastric cancer in the peritoneal cavity.
- Other names
- anti-HER2 chimeric antigen receptor macrophage cellsanti-HER-2 chimeric antigen receptor macrophage cellsanti-HER 2 chimeric antigen receptor macrophage cellsanti-HER2 CAR-M cellsanti-HER-2 CAR-M cellsanti-HER 2 CAR-M cellshuman anti-HER2 chimeric antigen receptor macrophageshuman HER2-targeted chimeric antigen receptor macrophageshuman HER2-targeted CAR-M cells
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on human HER2-targeted CAR-M cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human HER2-targeted CAR-M cells.